Display Settings:

Format

Send to:

Choose Destination
    Curr Alzheimer Res. 2006 Jul;3(3):197-9.

    Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate.

    Source

    Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel. igozes@post.tau.ac.il

    Abstract

    This short review outlines the scientific progression from the neuropeptide vasoactive intestinal peptide as a neuroprotective agent that acts through glial cells to increase and modulate the synthesis and secretion of novel neuroprotective substances. Recent development in the studies on activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF) and short peptide derivatives of these proteins, ADNF-9 and NAP suggest that these peptides are neurotrophic and promote neurite outgrowth. These short peptides hold promise in future neuroprotective/neurotrophic drug development. Clinical development of NAP is currently in progress by Allon Therapeutics, Inc.

    PMID:
    16842095
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Bentham Science Publishers Ltd.

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk